CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
CRISPR Therapeutics AG
NASDAQ:CRSPHealthcare · Biotechnology
-5.23%$51.42
AH$51.14-0.54%vs close
Mkt Cap$4.97B
Float78.42M
O/S96.69M
Vol
$ Vol
RVOL
Inst Own78.7%
SI21.0%
Earnings
Dilution
Financials Summary
Revenue$3.51M
Net Income-$581.6M
Total Assets$2.27B
Free Cash Flow-$345.93M
Debt & Equity
Debt 17%
Equity 83%
Total Debt$394.91M
Total Equity$1.92B
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in CRSP's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$2.27B
Liabilities$343.43M
Accounts Receivable$0
Accounts Payable$11.14M
Inventory$0
PP&E (Net)$247.57M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
| Revenue | $3.51M | $35M | $370M | $436K | $913.08M | $719K | $289.59M | $3.12M | $41M | $5.16M | $247K | $0 |
| YoY Growth | -90.0% | -90.5% | 84762.4% | -100.0% | 126893.2% | -99.8% | 9169.8% | -92.4% | 693.9% | 1990.7% | - | - |
| Cost of Revenue | $232.96M | $110.25M | $130.25M | $110.25M | $101.18M | $269.41M | $179.36M | $113.77M | $69.8M | $42.24M | $12.57M | $1.51M |
| Gross Profit | -$229.45M | -$75.25M | $239.75M | -$109.81M | $811.9M | -$268.69M | $110.23M | -$110.65M | -$28.8M | -$37.07M | -$12.33M | -$1.51M |
| Gross Margin | -6537.0% | -215.0% | 64.8% | -25186.7% | 88.9% | -37369.7% | 38.1% | -3541.9% | -70.3% | -717.9% | -4990.3% | - |
| Research and Development | $265.33M | $320.65M | $387.33M | $461.64M | $340.57M | $221.38M | $179.36M | $113.77M | $69.8M | $42.24M | $12.57M | $1.51M |
| Selling, General, and Administrative | $73.54M | $72.98M | $76.16M | $102.46M | $99.69M | $85.75M | $63.49M | $48.29M | $35.84M | $31.06M | $13.4M | $5.11M |
| Other | $0 | -$2.31M | -$1.21M | -$762K | -$1.88M | -$221.38M | -$179.36M | -$5.49M | -$197K | $78.51M | $16K | -$236K |
| Total Operating Expenses | $338.87M | $391.32M | $462.29M | $563.35M | $438.38M | $85.75M | $63.49M | $162.07M | $105.64M | $73.29M | $25.98M | $6.63M |
| Operating Income (EBIT) | -$568.32M | -$466.57M | -$222.54M | -$673.16M | $373.53M | -$354.44M | $46.74M | -$158.94M | -$64.65M | -$68.13M | -$25.73M | -$6.63M |
| Operating Margin | -16191.4% | -1333.0% | -60.1% | -154394.7% | 40.9% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% | -10416.6% | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 | - | $0 | $0 | $8.05M | $108K | $0 |
| Interest Income | $0 | $0 | $0 | $0 | $0 | $0 | - | $0 | $0 | $0 | $0 | $0 |
| Other Income (Expense) | -$9.65M | $103.9M | $71.82M | $22.66M | $6M | $6.38M | $20.57M | -$5.49M | -$1.96M | $45.41M | -$92K | -$236K |
| Income Before Tax (EBT) | -$577.97M | -$362.67M | -$150.72M | -$650.5M | $379.53M | -$348.06M | $67.31M | -$164.43M | -$66.61M | -$22.72M | -$25.82M | -$6.86M |
| Income Tax Expense | $3.63M | $3.59M | $2.89M | -$325K | $1.87M | $809K | $448K | $553K | $1.75M | $484K | $7K | -$63K |
| Net Income | -$581.6M | -$366.25M | -$153.61M | -$650.17M | $377.66M | -$348.87M | $66.86M | -$164.98M | -$68.36M | -$23.2M | -$25.83M | -$6.8M |
| Net Income Margin | -16569.8% | -1046.4% | -41.5% | -149122.7% | 41.4% | -48520.9% | 23.1% | -5281.1% | -166.7% | -449.3% | -10456.7% | - |
| Supplementary Data | ||||||||||||
| EPS | -6.47 | -4.34 | -1.94 | -8.36 | 4.97 | -5.29 | 1.23 | -3.44 | -1.71 | -1.89 | -0.88 | -0.23 |
| Diluted EPS | -6.47 | -4.34 | -1.94 | -8.36 | 4.70 | -5.29 | 1.17 | -3.44 | -1.71 | -1.89 | -0.88 | -0.23 |
| Weighted Average OS | 89.93M | 84.36M | 79.22M | 77.75M | 75.95M | 65.95M | 54.39M | 47.96M | 39.97M | 12.26M | 29.30M | 29.30M |
| EBITDA | -$558.49M | -$343.41M | -$130.88M | -$626.33M | $397.48M | -$345.25M | $51.47M | -$155.42M | -$61.62M | -$13.74M | -$25.59M | -$6.59M |
| EBITDA Margin | -15911.3% | -981.2% | -35.4% | -143653.2% | 43.5% | -48018.2% | 17.8% | -4975.2% | -150.3% | -266.1% | -10358.7% | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
| Assets | ||||||||||||
| Current Assets | ||||||||||||
| Cash and Cash Equivalents | $355.19M | $298.26M | $389.48M | $211.88M | $923.03M | $1.17B | $943.77M | $456.65M | $239.76M | $315.52M | $155.96M | $945K |
| Short-Term Investments | $1.63B | $1.61B | $1.3B | $1.6B | $1.46B | $521.71M | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $1.98B | $1.9B | $1.69B | $1.82B | $2.38B | $1.69B | $943.77M | $456.65M | $239.76M | $315.52M | $155.96M | $945K |
| Accounts Receivable | $0 | $25M | $200M | $0 | $305K | $10.84M | $99K | $88K | $2.63M | $3.16M | $339K | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $9.84M | $8.31M | $6.5M | $11.7M | $8.4M | $0 | $0 | $9.66M | $6M | $1.51M | $0 | $0 |
| Total Current Assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $987.55M | $466.39M | $248.38M | $320.19M | $156.84M | $968K |
| Long-Term Assets | ||||||||||||
| Property, Plant & Equipment Net | $247.57M | $277.55M | $305.94M | $320.56M | $312.04M | $93.03M | $72.83M | $18.5M | $18.86M | $21.03M | $1.33M | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $16K | $71K | $125K | $180K | $235K | $289K | $344K | $399K | $454K | $509K |
| Long-Term Investments | $0 | $0 | $1.97M | $53.13M | $0 | $0 | $5.04M | $3.16M | $3.15M | $3.15M | $700K | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | -$5.04M | -$3.16M | -$3.15M | -$3.15M | -$700K | $0 |
| Other Long-Term Assets | $32M | $27.35M | $13.57M | $16.27M | $22.2M | $18.14M | $6.14M | $3.83M | $3.76M | $3.35M | $801K | $50K |
| Total Long-Term Assets | $279.57M | $304.9M | $321.49M | $390.03M | $334.36M | $111.35M | $79.2M | $22.62M | $22.96M | $24.77M | $2.58M | $559K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489.02M | $271.35M | $344.96M | $159.42M | $1.53M |
| Liabilities | ||||||||||||
| Current Liabilities | ||||||||||||
| Accounts Payable | $11.14M | $14.71M | $38.15M | $27.43M | $14.82M | $9.09M | $5.94M | $5.07M | $1.64M | $4.57M | $1.58M | $211K |
| Short-Term Debt | $18.58M | $17.29M | $15.63M | $15.84M | $12.16M | $11.36M | $8.49M | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $451K | $0 | $0 | $0 | $10.47M | $583K | $402K | $347K | $23K | $81K | $11K |
| Current Unearned Revenue | $15.77M | $3.85M | $4.11M | $0 | $1.01M | $2.34M | $960K | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $89.55M | $33.05M | $33.13M | $58.46M | $67.51M | $38.59M | $25.9M | $14.95M | $6.97M | $14.82M | $9.3M | $1.8M |
| Total Current Liabilities | $149.12M | $87.78M | $108.79M | $121.11M | $119.88M | $94.26M | $57.11M | $27.75M | $14.51M | $22M | $10.15M | $2.15M |
| Long-Term Liabilities | ||||||||||||
| Long-Term Debt | $188.17M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $38.34M | $0 |
| Long-Term Unearned Revenue | $0 | $12.32M | $14.01M | $12.32M | $12.32M | $11.78M | $11.78M | $57.78M | $56.93M | $77.65M | $75.09M | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $64.52M | $0 |
| Other Long-Term Liabilities | -$182.03M | $3.44M | $958K | $5.97M | $7.34M | $7.63M | $14.39M | $11.29M | $12.07M | $12.47M | $542K | $85K |
| Total Long-Term Liabilities | $194.31M | $222.17M | $237.98M | $246.47M | $232.53M | $69.47M | $70.22M | $69.08M | $69M | $90.12M | $113.87M | $85K |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $343.43M | $309.95M | $346.77M | $367.58M | $352.42M | $163.73M | $127.33M | $96.82M | $83.51M | $112.12M | $188.55M | $8.5M |
| Stockholders' Equity | ||||||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $64.52M | $6.27M |
| Common Stock | $3.09M | $2.7M | $2.5M | $2.44M | $2.39M | $2.28M | $1.85M | $1.58M | $1.24M | $1.22M | $181K | $120K |
| Retained Earnings | -$1.95B | -$1.37B | -$999.7M | -$846.09M | -$195.91M | -$573.58M | -$224.71M | -$291.57M | -$125.44M | -$57.08M | -$33.91M | -$8.4M |
| Comprehensive Income & Other | $4.82M | $1.84M | $1.91M | -$15.65M | -$5.07M | -$83K | $7K | -$8K | $14K | -$26K | -$8K | -$2K |
| Other Stockholders' Equity | $3.87B | $3.3B | $2.88B | $2.72B | $2.59B | $2.24B | $1.16B | $682.18M | $312.03M | $288.71M | $4.63M | $1.17M |
| Total Equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.4B | $1.66B | $939.42M | $392.19M | $187.83M | $232.85M | -$29.1M | -$7.12M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$27K | $143K |
| Total Liabilities and Equity | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489.02M | $271.35M | $344.96M | $159.45M | $1.38M |
| Supplementary Data | ||||||||||||
| Total Debt | $394.91M | $223.69M | $238.63M | $244.02M | $225.03M | $61.43M | $52.54M | $0 | $0 | $0 | $38.34M | $0 |
| Net Debt | $39.73M | -$74.56M | -$150.84M | $32.14M | -$698M | -$1.11B | -$891.23M | -$456.65M | -$239.76M | -$315.52M | -$117.63M | -$945K |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
| Operating Activities | ||||||||||||
| Net Income | -$581.6M | -$366.25M | -$153.61M | -$650.17M | $377.66M | -$348.87M | $66.86M | -$164.98M | -$68.36M | -$23.2M | -$25.83M | -$6.8M |
| Depreciation & Amortization | $19.48M | $19.26M | $19.84M | $24.17M | $17.95M | $9.18M | $4.72M | $3.52M | $3.02M | $925K | $127K | $38K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $4.28M | $0 | -$53.71M | -$20K | $0 |
| Stock-Based Compensation | $72.5M | $86.57M | $81.03M | $97.95M | $102.39M | $66.02M | $44.06M | $34.98M | $18.87M | $10.84M | $3.68M | $695K |
| Changes in Working Capital: | ||||||||||||
| Accounts Receivable | $25M | $175M | -$200M | $305K | -$161K | -$45K | -$11K | $2.54M | $531K | -$2.82M | -$339K | $0 |
| Inventory | $0 | $0 | $0 | $0 | -$37.51M | -$25.75M | $0 | $332.3M | -$551.3M | -$1.09M | $0 | $0 |
| Accounts Payable | $44.89M | $0 | -$20.25M | $5.16M | $37.51M | $25.75M | $0 | -$323.28M | $546.62M | $3.86M | $0 | $0 |
| Other Working Capital | $1.99M | -$18.73M | $26.66M | $14.38M | $27.02M | $33.48M | -$48.42M | -$1M | -$21.24M | $1.83M | $81.71M | $1.53M |
| Total Working Capital Change | $71.88M | $156.27M | -$193.59M | $19.84M | $26.86M | $33.44M | -$48.43M | $10.55M | -$25.39M | $1.78M | $81.37M | $1.53M |
| Other Non-Cash Items | $72.72M | -$38.62M | -$14.04M | $12.47M | $14.11M | $1.86M | -$10.53M | $15.41M | $1.75M | $8.05M | $97K | -$260K |
| Net Cash from Operating | -$345.01M | -$142.77M | -$260.38M | -$495.74M | $538.97M | -$238.37M | $56.68M | -$96.24M | -$70.1M | -$55.31M | $59.43M | -$4.79M |
| Investing Activities | ||||||||||||
| Capital Expenditures | -$914K | -$1.9M | -$9.47M | -$37.19M | -$81.7M | -$18.36M | -$6.68M | -$2.77M | -$7.81M | -$3.02M | -$1.15M | $0 |
| Acquisitions | $0 | $0 | $0 | $221.47M | $953.73M | $522.81M | $0 | $0 | $0 | -$100K | $0 | $0 |
| Purchases of Investments | -$1.01B | -$1.49B | -$1.07B | -$1.42B | -$1.51B | -$594M | $0 | $0 | -$500K | -$100K | $0 | $0 |
| Sales of Investments | $1.01B | $1.21B | $1.45B | $1.2B | $555.6M | $71.19M | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | -$34M | $0 | -$2.5M | -$221.47M | -$953.73M | -$522.81M | $8.01M | $0 | -$500K | $35M | $0 | $0 |
| Net Cash from Investing | -$31.8M | -$280.48M | $374.65M | -$258.65M | -$1.04B | -$541.17M | $1.32M | -$2.77M | -$8.31M | $31.88M | -$1.15M | $0 |
| Financing Activities | ||||||||||||
| Debt Repaid | - | - | - | - | - | - | - | - | - | -$35.01M | -$38.24M | - |
| Common Stock Issuance | $426.03M | $300.69M | $62.66M | $970K | $213.27M | $982.29M | $415.02M | $307.05M | $2.61M | $89.06M | $58.49M | $22K |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$57K | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $31.29M | $0 | $37.62M | $37.68M | $33.86M | $15.96M | $8.94M | $2.61M | -$1.78M | -$127K | -$36K |
| Net Cash from Financing | $426.03M | $331.98M | $62.66M | $38.59M | $250.94M | $1.02B | $430.98M | $315.93M | $2.61M | $183.22M | $96.73M | $5.12M |
| Forex Effect | $95K | -$21K | $656K | -$80K | -$11K | $40K | $15K | -$22K | $41K | -$235K | $9K | $254K |
| Net Change in Cash | $49.3M | -$91.29M | $177.59M | -$715.88M | -$245.52M | $236.66M | $489M | $216.9M | -$75.76M | $159.56M | $155.02M | $584K |
| Supplementary Data | ||||||||||||
| Operating Cash Flow | -$345.01M | -$142.77M | -$260.38M | -$495.74M | $538.97M | -$238.37M | $56.68M | -$96.24M | -$70.1M | -$55.31M | $59.43M | -$4.79M |
| Capital Expenditure | -$914K | -$1.9M | -$9.47M | -$37.19M | -$81.7M | -$18.36M | -$6.68M | -$2.77M | -$7.81M | -$3.02M | -$1.15M | $0 |
| Free Cash Flow | -$345.93M | -$144.68M | -$269.85M | -$532.93M | $457.27M | -$256.72M | $49.99M | -$99.01M | -$77.91M | -$58.33M | $58.27M | -$4.79M |
| Cash at Beginning | $309.78M | $401.07M | $211.88M | $939.94M | $1.19B | $948.81M | $459.81M | $242.91M | $315.52M | $155.96M | $945K | $361K |
| Cash at End | $359.08M | $309.78M | $389.48M | $224.06M | $939.94M | $1.19B | $948.81M | $459.81M | $239.76M | $315.52M | $155.96M | $945K |